Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0L0ZF
|
||||
Former ID |
DNC003894
|
||||
Drug Name |
VESNARINONE
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Cardiac failure [ICD10:I50] | Approved | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C22H25N3O4
|
||||
Canonical SMILES |
COC1=C(C=C(C=C1)C(=O)N2CCN(CC2)C3=CC4=C(C=C3)NC(=O)CC4)<br />OC
|
||||
InChI |
1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
|
||||
InChIKey |
ZVNYJIZDIRKMBF-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 81840-15-5
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | CGMP-inhibited 3',5'-cyclic phosphodiesterase A | Target Info | Inhibitor | [2] | |
Potassium voltage-gated channel subfamily H member 2 | Target Info | Inhibitor | [3] | ||
KEGG Pathway | Purine metabolism | ||||
cGMP-PKG signaling pathway | |||||
cAMP signaling pathway | |||||
Morphine addiction | |||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | cGMP effects | ||||
G alpha (s) signalling eventsR-HSA-1296072:Voltage gated Potassium channels | |||||
WikiPathways | miR-targeted genes in muscle cell - TarBase | ||||
miR-targeted genes in lymphocytes - TarBaseWP706:SIDS Susceptibility Pathways | |||||
Hematopoietic Stem Cell Differentiation | |||||
Potassium Channels | |||||
References | |||||
REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
REF 2 | Bioorg Med Chem. 2010 Jan 15;18(2):855-62. Epub 2009 Nov 26.Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. | ||||
REF 3 | Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5.Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.